Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026
Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026
Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Fineline Cube Sep 1, 2026
Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Fineline Cube Sep 1, 2026
Company Deals

Nanjing Perlove Medical Equipment Files IPO Application in Hong Kong

Fineline Cube May 6, 2025

China-based Nanjing Perlove Medical Equipment Co., Ltd., a specialist in medical imaging and surgical robotics,...

Company Deals

Sanofi’s Opella Becomes Independent Consumer Healthcare Company After CD&R Deal

Fineline Cube May 6, 2025

Opella, the consumer health business of French pharmaceutical giant Sanofi (NASDAQ: SNY), became an independent...

Company Drug

Johnson & Johnson’s Imaavy Gains FDA Approval for Generalized Myasthenia Gravis

Fineline Cube May 6, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) unveiled a market approval in the United...

Company Drug

Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial

Fineline Cube May 6, 2025

China-based Chengdu Origen Biotechnology Co., Ltd. announced the first patient dosing of KH658, a gene...

Policy / Regulatory

China’s 13 Ministries Release Guidance to Optimize Primary Healthcare Institutions

Fineline Cube May 6, 2025

The National Health Commission, National Development and Reform Commission, and State Commission Office of Public...

Company Drug

AstraZeneca’s Breztri Aerosphere Meets Primary Endpoints in Phase III Asthma Trials

Fineline Cube May 6, 2025

UK-based pharmaceutical firm AstraZeneca (AZ; NASDAQ: AZN) this week unveiled results from the Phase III...

Company

Eli Lilly Reports 45% YOY Sales Growth in Q1 2025, Driven by Mounjaro and Zepbound

Fineline Cube May 6, 2025

US-based Eli Lilly & Co. (NYSE: LLY) released its Q1 2025 financial report, revealing sales...

Company Deals

Eucerin Partners with Guangzhou United Family Hospital for Dermatology Services

Fineline Cube May 6, 2025

Eucerin, the dermatology unit of Germany-based skincare firm Beiersdorf AG, has entered into a partnership...

Company Drug

Alphamab and CSPC Announce Positive Interim Results for KN026 in HER2+ Gastric Cancer Trial

Fineline Cube May 6, 2025

China-based firms Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the...

Company Drug

Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial

Fineline Cube Apr 30, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the first-in-human dosing of IBI3020, a first-in-class CEACAM5-targeted...

Company

Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025

Fineline Cube Apr 30, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial report, alongside its Q1...

Company Deals

Ipsen and Shanghai Pharmaceutical Partner to Expand Diphereline Coverage in China

Fineline Cube Apr 30, 2025

France-based Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the signing of a cooperation agreement with...

Company

Novartis Q1 2025 Results: Net Sales Up 15% YOY, Strong Growth in Key Brands

Fineline Cube Apr 30, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) released its Q1 2025 financial report, showing net sales...

Company

Merck Sharp & Dohme Announces $1 Billion Biologics Center in Wilmington, Delaware

Fineline Cube Apr 30, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) has announced the establishment of...

Company Deals

Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies

Fineline Cube Apr 30, 2025

Eli Lilly and Company (NYSE: LLY) announced a strategic collaboration with Creyon Bio, Inc., a...

Company Drug

AbbVie’s Rinvoq Gains FDA Approval for Giant Cell Arteritis

Fineline Cube Apr 30, 2025

US-based pharma giant AbbVie (NYSE: ABBV) announced regulatory approval from the US Food and Drug...

Company Drug

Bayer AG Launches Phase I Study of 225Ac-GPC3 for Advanced Hepatocellular Carcinoma

Fineline Cube Apr 30, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) has initiated a Phase I clinical study to...

Company Deals

Itcure and OBiO Technology Partner to Advance Gene Editing and VLP Delivery Systems

Fineline Cube Apr 30, 2025

Itcure, a gene editing specialist based in Suzhou, has entered into a partnership with compatriot...

Company Deals

Fosun Pharma Partners with Fakeeh Care Group to Advance Biopharmaceuticals in Saudi Arabia

Fineline Cube Apr 30, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced a strategic partnership...

Company

Fosun Pharma Reports Q1 2025 Revenues of RMB 9.42 Billion, Net Profits of RMB 765 Million

Fineline Cube Apr 30, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) released its Q1 2025...

Posts pagination

1 … 216 217 218 … 714

Recent updates

  • NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment
  • Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment
  • Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States
  • Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market
  • Laekna Doses First Patient in Phase I Study of LAE118 PI3Kα Inhibitor for Advanced Solid Tumors, Licensed to Vasque Bio for Up to USD 527 Million
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Company Drug

Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States

Policy / Regulatory

Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.